Investors Buy Large Volume of Call Options on Ekso Bionics (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) was the recipient of unusually large options trading activity on Tuesday. Stock investors bought 4,013 call options on the stock. This represents an increase of 3,217% compared to the average volume of 121 call options.

Several equities analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Ekso Bionics from a “sell” rating to a “hold” rating in a report on Friday, July 30th. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Ekso Bionics in a report on Friday, July 30th.

Institutional investors have recently added to or reduced their stakes in the business. Advisor Group Holdings Inc. lifted its holdings in Ekso Bionics by 1,492.5% during the 2nd quarter. Advisor Group Holdings Inc. now owns 6,402 shares of the company’s stock worth $35,000 after buying an additional 6,000 shares in the last quarter. Millennium Management LLC acquired a new stake in Ekso Bionics during the 1st quarter worth approximately $78,000. State Street Corp acquired a new stake in Ekso Bionics during the 2nd quarter worth approximately $76,000. Northern Trust Corp lifted its holdings in Ekso Bionics by 58.7% during the 1st quarter. Northern Trust Corp now owns 17,846 shares of the company’s stock worth $110,000 after buying an additional 6,599 shares in the last quarter. Finally, PEAK6 Investments LLC acquired a new stake in Ekso Bionics during the 2nd quarter worth approximately $107,000. Institutional investors own 10.05% of the company’s stock.

Shares of EKSO stock opened at $4.94 on Wednesday. The firm has a market cap of $62.52 million, a P/E ratio of -5.26 and a beta of 2.05. Ekso Bionics has a one year low of $3.96 and a one year high of $14.98. The company has a debt-to-equity ratio of 0.05, a quick ratio of 10.54 and a current ratio of 10.96. The firm’s 50 day moving average price is $4.67 and its 200-day moving average price is $5.40.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Wednesday, July 28th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.06. The company had revenue of $2.21 million for the quarter, compared to analyst estimates of $2.14 million. Ekso Bionics had a negative net margin of 69.75% and a negative return on equity of 54.22%. As a group, research analysts predict that Ekso Bionics will post -1.2 EPS for the current fiscal year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. It operates through the following segments: EksoHealth and EksoWorks. The EksoHealth segment consists of the engineering, manufacture and sale of exoskeletons for applications in the medical markets.

Featured Story: The limitations of an equal weight rating

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.